CVAC Stock Overview
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CureVac N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.91 |
52 Week High | US$12.36 |
52 Week Low | US$2.22 |
Beta | 2.51 |
1 Month Change | 50.38% |
3 Month Change | 18.48% |
1 Year Change | -58.54% |
3 Year Change | -96.48% |
5 Year Change | n/a |
Change since IPO | -93.01% |
Recent News & Updates
Recent updates
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
Mar 03CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma
Feb 04Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)
Jan 27CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates
Jan 11CureVac, Bayer agree to COVID-19 vaccine alliance - report
Jan 07Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?
Dec 23Curevac advances COVID-19 vaccine candidate to Phase 3 trial
Dec 21Shareholder Returns
CVAC | US Biotechs | US Market | |
---|---|---|---|
7D | 12.4% | 0.07% | -0.2% |
1Y | -58.5% | 6.9% | 28.2% |
Return vs Industry: CVAC underperformed the US Biotechs industry which returned 6.9% over the past year.
Return vs Market: CVAC underperformed the US Market which returned 28.2% over the past year.
Price Volatility
CVAC volatility | |
---|---|
CVAC Average Weekly Movement | 10.4% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CVAC's share price has been volatile over the past 3 months.
Volatility Over Time: CVAC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 1,086 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVac N.V. Fundamentals Summary
CVAC fundamental statistics | |
---|---|
Market cap | US$875.80m |
Earnings (TTM) | -US$281.75m |
Revenue (TTM) | US$58.22m |
15.0x
P/S Ratio-3.1x
P/E RatioIs CVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CVAC income statement (TTM) | |
---|---|
Revenue | €53.76m |
Cost of Revenue | €116.21m |
Gross Profit | -€62.45m |
Other Expenses | €197.71m |
Earnings | -€260.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
Earnings per share (EPS) | -1.16 |
Gross Margin | -116.17% |
Net Profit Margin | -483.96% |
Debt/Equity Ratio | 0% |
How did CVAC perform over the long term?
See historical performance and comparison